DXCM DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who suffered losses exceeding $100,000 during the specified class period to seek legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - The defendants are accused of making misleading statements regarding the reliability and functionality of the G6 and G7 devices, which led to increased regulatory scrutiny and potential financial harm to the company [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To participate in the class action, investors can visit the provided link or contact the firm directly for more information [3][6].